{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T10:28:11Z","timestamp":1794911291265,"version":"4.9.1"},"reference-count":51,"publisher":"BMJ","issue":"20","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:p>Natriuretic peptides, especially B-type natriuretic peptide (BNP), have primarily been regarded as biomarkers in heart failure (HF). However, they are also possible therapeutic agents due to their potentially beneficial physiological effects. The angiotensin receptor\u2013neprilysin inhibitor, sacubitril\/valsartan, simultaneously augments the natriuretic peptide system (NPS) by inhibiting the enzyme neprilysin (NEP) and inhibits the renin\u2013angiotensin\u2013aldosterone system (RAAS) by blocking the angiotensin II receptor. It has been shown to improve mortality and hospitalisation outcomes in patients with HF due to left ventricular systolic dysfunction. The key advantage of sacubitril\/valsartan has been perceived to be its ability to augment BNP, while its other effects have largely been overlooked. This review highlights the important effects of sacubitril\/valsartan, beyond just the augmentation of BNP. First we discuss how NPS physiology differs between healthy individuals and those with HF by looking at mechanisms like the overwhelming effects of RAAS on the NPS, natriuretic peptide receptor desensitisation and absolute natriuretic deficiency. Second, this review explores other hormones that are augmented by sacubitril\/valsartan such as bradykinin, substance P and adrenomedullin that may contribute to the efficacy of sacubitril\/valsartan in HF. We also discuss concerns that sacubitril\/valsartan may interfere with amyloid-\u03b2 homeostasis with potential implications on Alzheimer\u2019s disease and macular degeneration. Finally, we explore the concept of \u2018autoinhibition\u2019 which is a recently described observation that humans have innate NEP inhibitory capability when natriuretic peptide levels rise above a threshold. There is speculation that autoinhibition may provide a surge of natriuretic and other vasoactive peptides to rapidly reverse decompensation. We contend that by pre-emptively inhibiting NEP, sacubitril\/valsartan is inducing this surge earlier during decompensation, resulting in the better outcomes observed.<\/jats:p>","DOI":"10.1136\/heartjnl-2017-311295","type":"journal-article","created":{"date-parts":[[2017,7,8]],"date-time":"2017-07-08T20:10:31Z","timestamp":1499544631000},"page":"1569-1577","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":94,"title":["Sacubitril\/valsartan: beyond natriuretic peptides"],"prefix":"10.1136","volume":"103","clinical-trial-number":[{"clinical-trial-number":"nct01920711","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02884206","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02816736","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jagdeep S S","family":"Singh","sequence":"first","affiliation":[{"name":"Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise M","family":"Burrell","sequence":"additional","affiliation":[{"name":"Department of Medicine, Austin Health, The University of Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Cherif","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, Frimley Business Park, Frimley, Surrey, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B","family":"Squire","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester and Leicester NIHR Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Academic Cardiology, University of Hull, Daisy Building, Castle Hill Hospital, Castle Road, Cottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chim C","family":"Lang","sequence":"additional","affiliation":[{"name":"Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,7,8]]},"reference":[{"key":"2025091922305774000_103.20.1569.1","first-page":"283","article-title":"Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond","volume":"11","author":"Singh","year":"2015","journal-title":"Vasc Health Risk Manag"},{"key":"2025091922305774000_103.20.1569.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010713"},{"key":"2025091922305774000_103.20.1569.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077"},{"key":"2025091922305774000_103.20.1569.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.09.021"},{"key":"2025091922305774000_103.20.1569.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(01)00297-8"},{"key":"2025091922305774000_103.20.1569.6","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1590\/S0004-27302006000200006","article-title":"The broad homeostatic role of natriuretic peptides","volume":"50","author":"Maack","year":"2006","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"2025091922305774000_103.20.1569.7","doi-asserted-by":"publisher","DOI":"10.1210\/er.2005-0014"},{"key":"2025091922305774000_103.20.1569.8","doi-asserted-by":"publisher","DOI":"10.1124\/mol.104.002436"},{"key":"2025091922305774000_103.20.1569.9","doi-asserted-by":"crossref","unstructured":"Atlas S , Maack T . Atrial natriuretic factor. Handbook of physiology: Renal physiology. Renal physiology. New York: Oxford University Press, 1992:p.1577\u2013673.","DOI":"10.1002\/cphy.cp080233"},{"key":"2025091922305774000_103.20.1569.10","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.26.2.230"},{"key":"2025091922305774000_103.20.1569.11","first-page":"F546","article-title":"Clearance receptor and neutral endopeptidase-mediated metabolism of atrial natriuretic factor","volume":"263","author":"Okolicany","year":"1992","journal-title":"Am J Physiol"},{"key":"2025091922305774000_103.20.1569.12","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.87.1.70"},{"key":"2025091922305774000_103.20.1569.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.09.075"},{"key":"2025091922305774000_103.20.1569.14","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/0002-9343(88)90214-8","article-title":"Atrial natriuretic peptides and renin release","volume":"84","author":"Richards","year":"1988","journal-title":"Am J Med"},{"key":"2025091922305774000_103.20.1569.15","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.76.3_Suppl_3.36"},{"key":"2025091922305774000_103.20.1569.16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1042\/cs0740419","article-title":"Effects of angiotensin II and atrial natriuretic peptide alone and in combination on urinary water and electrolyte excretion in man","volume":"74","author":"McMurray","year":"1988","journal-title":"Clin Sci"},{"key":"2025091922305774000_103.20.1569.17","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(89)90273-2"},{"key":"2025091922305774000_103.20.1569.18","doi-asserted-by":"crossref","first-page":"14531","DOI":"10.1016\/S0021-9258(18)42069-8","article-title":"Dephosphorylation of the guanylyl cyclase-A receptor causes desensitization","volume":"267","author":"Potter","year":"1992","journal-title":"J Biol Chem"},{"key":"2025091922305774000_103.20.1569.19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.108.790774"},{"key":"2025091922305774000_103.20.1569.20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.110.960260"},{"key":"2025091922305774000_103.20.1569.21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.109.895581"},{"key":"2025091922305774000_103.20.1569.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.10.063"},{"key":"2025091922305774000_103.20.1569.23","unstructured":"Novartis Pharmaceuticals Canada Inc. Entresto (sacubitril \/ valsartan) Product monograph. 2016 https:\/\/www.novartis.ca\/sites\/www.novartis.ca\/files\/entresto_scrip_e.pdf (accessed 1 Nov 2016)."},{"key":"2025091922305774000_103.20.1569.24","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.7.5.575"},{"key":"2025091922305774000_103.20.1569.25","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.250"},{"key":"2025091922305774000_103.20.1569.26","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.146"},{"key":"2025091922305774000_103.20.1569.27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013748"},{"key":"2025091922305774000_103.20.1569.28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.018622"},{"key":"2025091922305774000_103.20.1569.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810293391804"},{"key":"2025091922305774000_103.20.1569.30","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.23.2305"},{"key":"2025091922305774000_103.20.1569.31","doi-asserted-by":"crossref","unstructured":"Laine P , Naukkarinen A , Heikkil\u00e4 L , et al ; Adventitial Mast cells connect with sensory nerve fibers in atherosclerotic coronary arteries, 2000. .doi:10.1161\/01.CIR.101.14.1665\u00a0","DOI":"10.1161\/01.CIR.101.14.1665"},{"key":"2025091922305774000_103.20.1569.32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0165-1838(86)90041-X","article-title":"Peptidergic innervation of human atrial myocardium: an electron microscopical and immunocytochemical study","volume":"17","author":"Rechardt","year":"1986","journal-title":"J Auton Nerv Syst"},{"key":"2025091922305774000_103.20.1569.33","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(90)90027-Y"},{"key":"2025091922305774000_103.20.1569.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.11.010"},{"key":"2025091922305774000_103.20.1569.35","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.83.6.2048"},{"key":"2025091922305774000_103.20.1569.36","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1993.279"},{"key":"2025091922305774000_103.20.1569.37","doi-asserted-by":"publisher","DOI":"10.1161\/hc4301.098252"},{"key":"2025091922305774000_103.20.1569.38","doi-asserted-by":"publisher","DOI":"10.1016\/S1357-2725(02)00273-X"},{"key":"2025091922305774000_103.20.1569.39","doi-asserted-by":"publisher","DOI":"10.1258\/cvd.2012.012008"},{"key":"2025091922305774000_103.20.1569.40","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.5.498"},{"key":"2025091922305774000_103.20.1569.41","doi-asserted-by":"publisher","DOI":"10.1038\/nm1438"},{"key":"2025091922305774000_103.20.1569.42","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/jnen\/61.10.849","article-title":"Declining expression of neprilysin in alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy","volume":"61","author":"Carpentier","year":"2002","journal-title":"J Neuropathol Exp Neurol"},{"key":"2025091922305774000_103.20.1569.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(00)01675-X"},{"key":"2025091922305774000_103.20.1569.44","doi-asserted-by":"crossref","unstructured":"Cannon JA , Shen L , Jhund PS , et al . Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail 2017;19.doi:10.1002\/ejhf.687","DOI":"10.1002\/ejhf.687"},{"key":"2025091922305774000_103.20.1569.45","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12861"},{"key":"2025091922305774000_103.20.1569.46","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2984-08.2009"},{"key":"2025091922305774000_103.20.1569.47","unstructured":"New drug application approval letter: US Food and Drug Administration, 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2015\/207620Orig1s000ltr.pdf. (accessed 24 Aug 2016)."},{"key":"2025091922305774000_103.20.1569.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2011.02.004"},{"key":"2025091922305774000_103.20.1569.49","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.exer.2015.06.027","article-title":"Reduction of amyloid-beta levels in mouse eye tissues by\u00a0intra-vitreally delivered neprilysin","volume":"138","author":"Parthasarathy","year":"2015","journal-title":"Exp Eye Res"},{"key":"2025091922305774000_103.20.1569.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2015.03.011"},{"key":"2025091922305774000_103.20.1569.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.09.931"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2017-311295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T05:31:05Z","timestamp":1758346265000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2017-311295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,8]]},"references-count":51,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2017,10,2]]},"published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1136\/heartjnl-2017-311295"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2017-311295","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,8]]}}}